חזרה לתוצאות החיפוש

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE3

מצבים רפואיים

Prostate Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Stanford University Medical Center, Palo Alto, California, United States

    Contact: Study coordinator (Tiffany Chen) · tiff1221@stanford.edu
    Contact: Principal Investigator (Hong Song)

  • Sansum Clinic, Santa Barbara, California, United States

    Contact: Study coordinator (Megan Martinez) · megan.martinez@sutterhealth.or · 805-563-5800
    Contact: Principal Investigator (Mukul Gupta)

  • Rocky Mountain Cancer Centers, Denver, Colorado, United States

    Contact: Study coordinator (Bethany Glatthar) · Bethany.Glatthar@usoncology.com · 303-839-6530
    Contact: Principal Investigator (Allen Cohn)

  • Baptist Health South, Miami, Florida, United States

    Contact: Study coordinator (Leslie Castaneda) · leslie.castaneda@baptisthealth.net
    Contact: Principal Investigator (Rohan Garje)

  • AdventHealth, Orlando, Florida, United States

    Contact: Study coordinator (Joseph Guzzo) · joseph.guzzo@adventhealth.com · 407-303-3235
    Contact: Principal Investigator (Ravi Shridhar)

  • Northwestern University, Chicago, Illinois, United States

    Contact: Study coordinator (Rachel Hanna Springsdorf) · rachelspringsdorf@northwestern.edu · +1 312 695 1382
    Contact: Principal Investigator (Maha Hussain)

  • Univ Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States

    Contact: Study coordinator (Kellie Bodeker) · kellie-bodeker@uiowa.edu
    Contact: Principal Investigator (Kristin Plichta)

  • University of Kansas Hospital, Kansas City, Kansas, United States

    Contact: Study coordinator (Collin Bruey) · cbruey@kumc.edu
    Contact: Principal Investigator (Xinglei Shen)

  • East Jefferson Hospital, Metairie, Louisiana, United States

    Contact: Study coordinator (Alexandra Lieberman) · alexandra.lieberman@lcmchealth.org
    Contact: Principal Investigator (Alton Oliver Sartor)

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Amanda Lilienfeld) · amanda_lilienfeld@dfci.harvard.edu
    Contact: Principal Investigator (Xiao Wei)

  • Wash U School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Collin Welch) · c.welch@wustl.edu
    Contact: Principal Investigator (Jeff Michalski)

  • Nebraska Cancer Specialists, Omaha, Nebraska, United States

    Contact: Study coordinator (Marlene Bridwell) · mbridwell@nebraskacancer.com
    Contact: Principal Investigator (Samuel Mehr)

  • New Jersey Urology LLC, Voorhees Township, New Jersey, United States

    Contact: Study coordinator (Gabriela Mercado) · gmercado3@nj-urology.com · 856-673-1613
    Contact: Principal Investigator (Gordon Brown)

  • Bassett Medical Center, Cooperstown, New York, United States

    Contact: Study coordinator (Peggy Cross) · peggy.cross@bassett.org
    Contact: Principal Investigator (Timothy Korytko)

  • Weill Cornell Medicine NY-Presb, New York, New York, United States

    Contact: Study coordinator (Sarah Yuan) · say7008@med.cornell.edu · 646-962-2535
    Contact: Principal Investigator (Scott Tagawa)

  • University of Rochester Medical Ctr, Rochester, New York, United States

    Contact: Study coordinator (Therese Smudzin) · Therese_Smudzin@urmc.rochester.edu
    Contact: Principal Investigator (Haoming Carl Qiu)

  • Associated Med Professionals of NY, Syracuse, New York, United States

    Contact: Study coordinator (Nathan Forrest) · nathan.forrest@ampofny.com
    Contact: Principal Investigator (Steven Finkelstein)

  • Montefiore Medical Center, The Bronx, New York, United States

    Contact: Study coordinator (Tahrima Chowdhury) · tahchowdhu@montefiore.org · 718-920-2680
    Contact: Principal Investigator (Benjamin A Gartrell)

  • Central Ohio Urology Group, Gahanna, Ohio, United States

    Contact: Study coordinator (Tosha Heineman) · tosha@optimedresearch.com
    Contact: Principal Investigator (Benjamin Martin)

  • MUSC Hollings Cancer Center, Charleston, South Carolina, United States

    Contact: Study coordinator (Alex Jones) · joalex@musc.edu
    Contact: Principal Investigator (Kevin Becker)

  • Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States

    Contact: Study coordinator (Rebecca Floyd) · rebecca.floyd@startresearch.com · 843-839-1679
    Contact: Principal Investigator (Neal D Shore)

  • Urology San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Sandra Davila) · sandra.davila@usa-clinicaltrials.com
    Contact: Principal Investigator (Daniel Saltzstein)

  • Woodlands Cancer Institute American Oncology Partners, The Woodlands, Texas, United States

    Contact: Study coordinator (Brittany Rogers) · brittany.rogers@aoncology.com
    Contact: Principal Investigator (Jason Berilgen)

  • Swedish Medical Center, Seattle, Washington, United States

    Contact: Study coordinator (Brianna McNealley) · brianna.mcnealley@swedish.org · 855-922-6237
    Contact: Principal Investigator (Song Zhao)

  • Medical College of Wisconsin, Milwaukee, Wisconsin, United States

    Contact: Study coordinator (Mariah Ziegler) · mziegler@mcw.edu · 414-805-5249
    Contact: Principal Investigator (Deepak Kilari)

  • Novartis Investigative Site, Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site, Adelaide, South Australia, Australia

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Fuzhou, Fujian, China

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Wuhan, Hubei, China

  • Novartis Investigative Site, Wuhan, Hubei, China

  • Novartis Investigative Site, Nanjing, Jiangsu, China

  • Novartis Investigative Site, Nanjing, Jiangsu, China

  • Novartis Investigative Site, Shenyang, Liaoning, China

  • Novartis Investigative Site, Chengdu, Sichuan, China

  • Novartis Investigative Site, Hangzhou, Zhejiang, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Guangzhou, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Tianjin, China

  • Novartis Investigative Site, Hong Kong, Hong Kong

  • Novartis Investigative Site, Gurgaon, Haryana, India

  • Novartis Investigative Site, Bengaluru, Karnataka, India

  • Novartis Investigative Site, Mumbai, Maharashtra, India

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Kobe, Hyōgo, Japan

  • Novartis Investigative Site, Kobe, Hyōgo, Japan

  • Novartis Investigative Site, Yokohama, Kanagawa, Japan

  • Novartis Investigative Site, Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site, Chiba, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukushima, Japan

  • Novartis Investigative Site, Hiroshima, Japan

  • Novartis Investigative Site, Kyoto, Japan

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taoyuan, Taiwan

  • Novartis Investigative Site, Sutton, Surrey, United Kingdom

מובילי המחקר

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)